BioSpace News Archive

Sionna Therapeutics, a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today announced the formation of a Scientific Advisory Board (SAB).

Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will participate in the “Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need” panel discussion on Tuesday, August 9, 2022, 1:00 pm (ET).

ENDRA Life Sciences to Participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference.

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, provided an overview of its strategic growth plan in conjunction with its corporate name change today.

Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced its plans to release financial results for its second quarter ended June 30, 2022 after the close of trading on August 9, 2022.

BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), announced today that the journal of International Journal of Health Sciences1 released a peer-reviewed article, “Carbohydrate ProLectin-M, a Galectin-3 Antagonist, Blocks SARS-CoV-2 Activity”, that supports ProLectin-M’s in vitro Mode of Action and the initial clinical data results reported in a previous article, referred to below.

BrainCheck Inc., developer of an innovative digital cognitive assessment and care platform, announced an Investigator Initiated Research Grant Program to help fund research for evaluation, diagnosis, treatment and care for brain related disease.

Renegade.bio, an LGBTQ-owned public benefit corporation, announced today that it has begun processing highly sensitive and accurate, polymerase chain reaction (PCR) monkeypox tests for San Francisco and California at large, delivering test results in 24 hours through partnerships with surrounding clinics and hospitals.

Portage Biotech Inc., a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, announced financial results for the fiscal year ended March 31, 2022.

BioInvent International AB announces treatment of the first patient in a Phase 1/2a trial of its second anti-FcyRIIB antibody BI-1607 in combination with trastuzumab in HER2+ solid tumors.